This fall, CMS will start sharing monthly utilization reports with Part D plans on how their enrollees are using the Medicare GLP-1 Bridge program.
The agency said in an Aug. 5 memo that the reports will be organized at both the contract and plan level and will include claims-level data such as the date of service, drug dispensed, quantity, days supply, prescriber, fill number and beneficiary identifier. All Part D plans will be covered, except for PACE organizations, cost plans and private fee-for-service plans.
CMS uses a central processor to handle prior authorization, claims adjudication and pharmacy reimbursement, meaning Part D sponsors don’t carry risk for GLP-1 drugs furnished through the demonstration. The utilization reports would give insurers a window into how their own members are using the program despite having no direct role in administering it.
The Bridge program launched July 1 and runs through the end of 2027. It provides eligible Part D beneficiaries access to Wegovy, Zepbound and Foundayo for weight management at a $50 monthly copay. Manufacturers provide the drugs at a net price of $245, with CMS covering the remaining $195.
CMS originally intended to transition GLP-1 weight loss coverage into Part D benefits through the voluntary BALANCE model, but shelved that component indefinitely after insufficient sponsor participation. The Bridge program was extended through 2027 as a result.
At the time of the BALANCE delay, CMS had said it planned to share Bridge utilization data with sponsors ahead of any future implementation of the model in Part D.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
